Based on the results that EPHA1, EPHA2 and EFNA1 are differentially expressed in metastatic compared to primary tissue, the EPH kinases and/or their ligands represent attractive candidates for a targeted treatment of metastatic ccRCC. This evidence concerns the gene EPHA1 and nonpapillary renal cell carcinoma.